Literature DB >> 25556809

Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.

Paul P Lerner1, Chanoch Miodownik2, Vladimir Lerner2.   

Abstract

Tardive dyskinesia is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking psychotropic drugs. The pathophysiology of tardive dyskinesia is complex, multifactorial and still not fully understood. A number of drugs were tried for the management of this motor disturbance, yet until now no effective and standard treatment has been found. It is very disappointing to realize that the introduction of antipsychotics from the second generation has not significantly decreased the prevalence and incidence of tardive dyskinesia. Therefore, the management of this motor disturbance remains an actual topic as well as a challenge for clinicians. This review summarizes recent relevant publications concerning the treatment of tardive dyskinesia.
© 2014 The Authors. Psychiatry and Clinical Neurosciences © 2014 Japanese Society of Psychiatry and Neurology.

Entities:  

Keywords:  first-generation agents; management; schizophrenia; second-generation agents; tardive dyskinesia

Mesh:

Substances:

Year:  2015        PMID: 25556809     DOI: 10.1111/pcn.12270

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  21 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

2.  Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center.

Authors:  Sandra Steingard
Journal:  Community Ment Health J       Date:  2018-08-03

3.  High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.

Authors:  Musa U Umar; Aliyu A Isa; Asmaul H Abba
Journal:  Ther Adv Psychopharmacol       Date:  2015-12-14

Review 4.  VMAT2 Inhibitors in Neuropsychiatric Disorders.

Authors:  Arjun Tarakad; Joohi Jimenez-Shahed
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

5.  Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Authors:  Fernanda F Peres; Raquel Levin; Mayra A Suiama; Mariana C Diana; Douglas A Gouvêa; Valéria Almeida; Camila M Santos; Lisandro Lungato; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; D'Almeida Vânia; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

Review 6.  Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.

Authors:  Ryoma Morigaki; Hideo Mure; Ryuji Kaji; Shinji Nagahiro; Satoshi Goto
Journal:  Front Psychiatry       Date:  2016-12-26       Impact factor: 4.157

7.  Long-Term Follow-Up of 12 Patients Treated with Bilateral Pallidal Stimulation for Tardive Dystonia.

Authors:  Hiroshi Koyama; Hideo Mure; Ryoma Morigaki; Ryosuke Miyamoto; Kazuhisa Miyake; Taku Matsuda; Koji Fujita; Yuishin Izumi; Ryuji Kaji; Satoshi Goto; Yasushi Takagi
Journal:  Life (Basel)       Date:  2021-05-24

8.  Clozapine-induced Tardive Dyskinesia.

Authors:  Soumitra Das; Sumesh Thoppil Purushothaman; Varun Rajan; Seshadri Sekhar Chatterjee; Arjun Kartha
Journal:  Indian J Psychol Med       Date:  2017 Jul-Aug

9.  MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.

Authors:  Dong Xu; Alexandrea G Ham; Rickey D Tivis; Matthew L Caylor; Aoxiang Tao; Steve T Flynn; Peter J Economen; Hung K Dang; Royal W Johnson; Vaughn L Culbertson
Journal:  EBioMedicine       Date:  2017-11-22       Impact factor: 8.143

Review 10.  Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Authors:  Fernanda F Peres; Alvaro C Lima; Jaime E C Hallak; José A Crippa; Regina H Silva; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2018-05-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.